BSE filing, NSE: EMMESSA. Summary written from the filing by ALFA Finder's alert engine.
Emmessar Biotech & Nutrition Ltd: key numbers
- Share price
- ₹23.63
- Market cap
- ₹11.81 Cr
- Revenue (annual)
- ₹0.37 Cr
- Net profit (annual)
- ₹0.44 Cr
- P/E (TTM)
- 29.8×Sector 52.8×
- Promoter holding
- 59.53%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Emmessar Biotech & Nutrition Ltd
All →Emmessar Biotech & Nutrition Board Meeting Date
Emmessar Biotech & Nutrition scheduled a board meeting for 31 October 2026 to consider unaudited quarterly results ended 30 September 2026. The trading window stays closed until 02 November 2026.
Emmessar Biotech & Nutrition Other Announcement
Emmessar Biotech & Nutrition Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with regulatory reporting standards.
Emmessar Biotech & Nutrition Annual General Meeting
Emmessar Biotech & Nutrition Ltd conducted its 34th Annual General Meeting on September 29, 2026. Key business included adopting financial statements and re-appointing directors.
Emmessar Biotech & Nutrition Other Announcement
Emmessar Biotech & Nutrition informed shareholders without registered email addresses about accessing the Annual Report and 34th AGM Notice via the company's website.
Emmessar Biotech & Nutrition Annual General Meeting
Emmessar Biotech & Nutrition Limited has issued a notice for its 34th Annual General Meeting, scheduled to be held on September 29, 2026, via video conferencing.
Emmessar Biotech & Nutrition Q1 FY27 Results: Net Profit ₹0.1 Cr, Down 50.0% YoY
Emmessar Biotech & Nutrition Ltd reported revenue from operations of ₹0.1 Cr (+0.0% YoY) and net profit of ₹0.1 Cr (-50.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹0.1 Cr · -50.0% YoY
Other debt & borrowing announcements
All →LIC Housing Finance Debt & Borrowing
LIC Housing Finance reported a 1.24x security cover on listed secured NCDs. It is a Regulation 54 certificate with no new event amount.
Religare Enterprises Debt & Borrowing: ₹150 Cr
Care Health Insurance, a material subsidiary of Religare, allotted listed subordinated debentures worth ₹150 Crore at a 10.50% coupon. The debentures mature in 2036, callable after five years.
- Value
- ₹150.0 Cr
Blue Coast Hotels Debt & Borrowing: ₹14.52 Cr
Blue Coast Hotels defaulted on Rs 14.52 crore principal and dividend on redeemable preference shares. Default occurred 30 October 2026, affecting unlisted debt holders.
- Value
- ₹14.52 Cr
Sammaan Capital Debt & Borrowing: ₹0.88 Cr
Sammaan Capital paid Rs.0.88 Crore of monthly interest on secured NCDs on October 30, 2026, ahead of the November 1 due date.
- Value
- ₹0.88 Cr
Sammaan Capital Debt & Borrowing: ₹0.58 Cr
Sammaan Capital certifies timely payment of Rs 0.58 crore interest on listed public-issue NCDs. The payment covers seven ISINs, with interest paid on October 30, 2026.
- Value
- ₹0.58 Cr
Lodha Developers Debt & Borrowing: ₹300 Cr
Lodha Developers disclosed utilisation of ₹300 Crore from its 30 June 2026 NCD private placement, with no deviation. The Reg 52(7) statement covers the quarter ended 30 September 2026.
- Value
- ₹300.0 Cr